Sanofi AI Drug Discovery Deal Bolsters Baidu-Backed Startup BioMap
But Field Faces Data, Other Challenges
As artificial intelligence-aided drug discovery gains momentum, Sanofi appears keen to hop onboard via a recent tie-up with leading Chinese AI company BioMap. But data challenges, a hard-to-define value proposition, concerns over data security and looming regulations are making others hesitant.
You may also be interested in...
Topics in this latest Chinese-language podcast include the US approval of Chinese innovative drugs including Junshi’s anti-PD-1 antibody toripalimab, Sanofi’s deal with BioMap for AI-powered drug discovery, Chinese companies' third-quarter results and the Biden-Xi summit on the sidelines of APEC and its implications for bilateral regulatory dialog.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.